COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women.

Autor: Atyeo C; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.; PhD Program in Virology, Division of Medical Sciences, Harvard University, Boston, MA 02115, USA., DeRiso EA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA., Davis C; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Bordt EA; Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA., De Guzman RM; Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.; Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA 02114, USA., Shook LL; Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.; Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA 02114, USA., Yonker LM; Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA 02115, USA.; Department of Pediatrics, Massachusetts General Hospital, Boston, MA 02115, USA.; Harvard Medical School, Boston, MA 02115, USA., Fasano A; Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA 02115, USA.; Department of Pediatrics, Massachusetts General Hospital, Boston, MA 02115, USA.; Harvard Medical School, Boston, MA 02115, USA., Akinwunmi B; Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Lauffenburger DA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Elovitz MA; Maternal and Child Health Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Gray KJ; Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Edlow AG; Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.; Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA 02114, USA., Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Jazyk: angličtina
Zdroj: Science translational medicine [Sci Transl Med] 2021 Oct 27; Vol. 13 (617), pp. eabi8631. Date of Electronic Publication: 2021 Oct 27.
DOI: 10.1126/scitranslmed.abi8631
Abstrakt: Substantial immunological changes occur throughout pregnancy to render the mother immunologically tolerant to the fetus and allow fetal growth. However, additional local and systemic immunological adaptations also occur, allowing the maternal immune system to continue to protect the dyad against pathogens both during pregnancy and after birth through lactation. This fine balance of tolerance and immunity, along with physiological and hormonal changes, contributes to increased susceptibility to particular infections in pregnancy, including more severe coronavirus disease 2019 (COVID-19). Whether these changes also make pregnant women less responsive to vaccination or induce altered immune responses to vaccination remains incompletely understood. To define potential changes in vaccine response during pregnancy and lactation, we undertook deep sequencing of the humoral vaccine response in a group of pregnant and lactating women and nonpregnant age-matched controls. Vaccine-specific titers were comparable between pregnant women, lactating women, and nonpregnant controls. However, Fc receptor (FcR) binding and antibody effector functions were induced with delayed kinetics in both pregnant and lactating women compared with nonpregnant women after the first vaccine dose, which normalized after the second dose. Vaccine boosting resulted in high FcR-binding titers in breastmilk. These data suggest that pregnancy promotes resistance to generating proinflammatory antibodies and indicates that there is a critical need to follow prime-boost timelines in this vulnerable population to ensure full immunity is attained.
Databáze: MEDLINE